BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 20121564)

  • 1. Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents.
    Rossini R; Musumeci G; Aprile A; Valsecchi O
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):49-61. PubMed ID: 20121564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?
    Valgimigli M; Airoldi F; Zimarino M
    J Cardiovasc Med (Hagerstown); 2009 Oct; 10 Suppl 1():S17-26. PubMed ID: 19851216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stent thrombosis with drug-eluting stents: a re-examination of the evidence.
    Kedia G; Lee MS
    Catheter Cardiovasc Interv; 2007 May; 69(6):782-9. PubMed ID: 17394249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting coronary artery stents.
    Dehmer GJ; Smith KJ
    Am Fam Physician; 2009 Dec; 80(11):1245-51. PubMed ID: 19961137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conundrum of late and very late stent thrombosis following drug-eluting stent implantation.
    Garg P; Mauri L
    Curr Opin Cardiol; 2007 Nov; 22(6):565-71. PubMed ID: 17921745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
    J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based management of patients undergoing PCI: stent controversies.
    Vetrovec GW
    Catheter Cardiovasc Interv; 2010 Mar; 75 Suppl 1():S39-42. PubMed ID: 20333706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug-eluting stents in multivessel coronary artery disease: Was one of the important fortresses of surgery conquered?].
    Okmen AS; Okmen E
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):325-30. PubMed ID: 19666436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of drug-eluting stents.
    Windecker S; Jüni P
    Nat Clin Pract Cardiovasc Med; 2008 Jun; 5(6):316-28. PubMed ID: 18414453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late stent thrombosis with drug eluting stents: disturbing signals on the radar].
    Hansen PR
    Ugeskr Laeger; 2007 Apr; 169(17):1561-3. PubMed ID: 17484825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stent thrombosis in the era of drug eluting stents.
    Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
    Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.
    Ducrocq G; Serebruany V; Tanguay JF
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):939-53. PubMed ID: 17867923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
    Kumbhani DJ; Bavry AA; Bhatt DL
    Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.